Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

New Challenges in (Bio)Analytical Sample Treatment Procedures for Clinical Applications

View through CrossRef
The primary cause of poor and ambiguous results obtained from the bioanalytical process is the sample pre-treatment, especially in clinical analysis because it involves dealing with complex sample matrices, such as whole blood, urine, saliva, serum, and plasma. So, the aim of this review is to focus attention on the classical and new techniques of pre-treatment for biological samples used in the bioanalytical process. We discussed the methods generally used for these types of complex samples. Undoubtedly, it is a daunting task to deal with biological samples because the analyst may encounter a substantial loss of the analytes of interest, or the overall analysis may be too time-consuming. Nowadays, we are inclined to use green solvents for the environment, but without sacrificing analytical performance and selectivity. All the characteristics mentioned above should be added to the difficulty of the withdrawal of samples like blood because it can be an invasive practice. For these reasons, now we can also find in the literature the use of saliva as alternative biological samples and new techniques that do not require substantial sample pre-treatment, such as fabric phase sorptive extraction (FPSE). The text has been divided into the following two distinct parts: firstly, we described clinical applications under different subsections, such as anticancer drugs, antibiotics, vitamins, antivirals, non-steroidal anti-inflammatory drugs, statin, imidazoles, and triazoles. The second part is dedicated to sample preparation techniques for diagnostic purposes and is divided into the following different sample preparation techniques: solid-phase microextraction (SPME), microextraction by packed sorbent (MEPS), dispersive liquid–liquid microextraction (DDLME), and fabric phase sorptive extraction (FPSE).
Title: New Challenges in (Bio)Analytical Sample Treatment Procedures for Clinical Applications
Description:
The primary cause of poor and ambiguous results obtained from the bioanalytical process is the sample pre-treatment, especially in clinical analysis because it involves dealing with complex sample matrices, such as whole blood, urine, saliva, serum, and plasma.
So, the aim of this review is to focus attention on the classical and new techniques of pre-treatment for biological samples used in the bioanalytical process.
We discussed the methods generally used for these types of complex samples.
Undoubtedly, it is a daunting task to deal with biological samples because the analyst may encounter a substantial loss of the analytes of interest, or the overall analysis may be too time-consuming.
Nowadays, we are inclined to use green solvents for the environment, but without sacrificing analytical performance and selectivity.
All the characteristics mentioned above should be added to the difficulty of the withdrawal of samples like blood because it can be an invasive practice.
For these reasons, now we can also find in the literature the use of saliva as alternative biological samples and new techniques that do not require substantial sample pre-treatment, such as fabric phase sorptive extraction (FPSE).
The text has been divided into the following two distinct parts: firstly, we described clinical applications under different subsections, such as anticancer drugs, antibiotics, vitamins, antivirals, non-steroidal anti-inflammatory drugs, statin, imidazoles, and triazoles.
The second part is dedicated to sample preparation techniques for diagnostic purposes and is divided into the following different sample preparation techniques: solid-phase microextraction (SPME), microextraction by packed sorbent (MEPS), dispersive liquid–liquid microextraction (DDLME), and fabric phase sorptive extraction (FPSE).

Related Results

Environmental Surveillance Protocols for Highly Pathogenic Avian Influenza (HPAI) v2
Environmental Surveillance Protocols for Highly Pathogenic Avian Influenza (HPAI) v2
EnvironmentalSurveillance Protocols for Highly Pathogenic Avian Influenza (HPAI) This comprehensive protocol suite enables systematic environmental surveillance for avian influenza...
Isolation And Characterization Of Biosurfactant Producing Bacteria From Different Environmental Soil Samples
Isolation And Characterization Of Biosurfactant Producing Bacteria From Different Environmental Soil Samples
Biosurfactants are natural substances produced by several bacterial and fungal organisms that are amphiphilic and are extracellular (a part of the cell membrane). Biosurfactants ca...
STUDY ON THE EFFECT OF TEMPERATURE ON BIO-ETHANOL PRODUCTION FROM CASSAVA FLOUR AND CASSAVA PEELS: AN INSIGHT INTO BIO-ENERGY PROCESSES
STUDY ON THE EFFECT OF TEMPERATURE ON BIO-ETHANOL PRODUCTION FROM CASSAVA FLOUR AND CASSAVA PEELS: AN INSIGHT INTO BIO-ENERGY PROCESSES
Knowledge of fermentation parameters with respect to temperature is necessary in bio-ethanol production; as an important process in bio-energy applications for green energy utiliza...
GROWTH PERFORMANCE OF TISSUE-CULTURED ´LAKATAN´ BANANA (MUSA ACUMINATA) PLANTLETS USING STIMULANTS
GROWTH PERFORMANCE OF TISSUE-CULTURED ´LAKATAN´ BANANA (MUSA ACUMINATA) PLANTLETS USING STIMULANTS
The study aimed to determine the effects of stimulants on the growth performance of tissue-cultured 'lakatan' banana plantlets (Musa acuminata) under nursery condition; to determin...
7 th International Symposium on Enabling Technologies for Life Sciences (ETP)
7 th International Symposium on Enabling Technologies for Life Sciences (ETP)
The seventh in the series of ETP Symposia (see Rapid Communications in Mass Spectrometry 2012, 26 , ...
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...

Back to Top